Enbrel is one of the top ten drugs in the U.S. by sales, garnering the pharmaceutical giants who co-market the drug, Amgen and Pfizer, billions of dollars in revenue annually. People take Enbrel for ...

Americans with psoriasis and rheumatoid arthritis will have to wait much longer for low-priced copycat versions of their weekly Enbrel injections. Amgen (AMGN 1.17%) won an appeals court ruling on ...

The psoriasis-easing effect of Enbrel, a drug that dampens inflammatory immune responses, lasts for at least two years, a large-scale clinical trial shows. Enbrel acts like a very specific sponge that ...

Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...

THOUSAND OAKS, Calif., November 12, 2006 -- Amgen (NASDAQ: AMGN) today announced that Enbrel? (etanercept) is the first biologic with published data to show improvements in multiple measures of ...

A patent fight has already delayed Sandoz' biosimilar version of Amgen's anti-inflammatory blockbuster Enbrel. And now, it looks as if Sandoz will have to wait a little longer for a clear shot at the ...

Wall Street analysts projected a gradual fall in the revenue for Amgen’s (AMGN) blockbuster inflammation drug Enbrel and its leading neutropenia drug Neulasta in 4Q15 and fiscal 1Q16. The above chart ...

Add Yahoo as a preferred source to see more of our stories on Google. U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that ...

Never fear, makers of anti-TNF giants: Those pesky biosimilars? They won’t be halting revenue growth anytime soon, Leerink Partners analysts predict. Taking into account current trends in prescription ...

The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and ...